These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 31495881)

  • 1. Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial.
    Perkovic V; Koitka-Weber A; Cooper ME; Schernthaner G; Pfarr E; Woerle HJ; von Eynatten M; Wanner C
    Nephrol Dial Transplant; 2020 Dec; 35(12):2103-2111. PubMed ID: 31495881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME
    Kadowaki T; Nangaku M; Hantel S; Okamura T; von Eynatten M; Wanner C; Koitka-Weber A
    J Diabetes Investig; 2019 May; 10(3):760-770. PubMed ID: 30412655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Waijer SW; Xie D; Inzucchi SE; Zinman B; Koitka-Weber A; Mattheus M; von Eynatten M; Inker LA; Wanner C; Heerspink HJL
    J Am Heart Assoc; 2020 Sep; 9(18):e016976. PubMed ID: 32893717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
    Levin A; Perkovic V; Wheeler DC; Hantel S; George JT; von Eynatten M; Koitka-Weber A; Wanner C;
    Clin J Am Soc Nephrol; 2020 Oct; 15(10):1433-1444. PubMed ID: 32994159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
    Wanner C; Heerspink HJL; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; Hantel S; Woerle HJ; Broedl UC; von Eynatten M; Groop PH;
    J Am Soc Nephrol; 2018 Nov; 29(11):2755-2769. PubMed ID: 30314978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Ferreira JP; Kraus BJ; Zwiener I; Lauer S; Zinman B; Fitchett DH; Koitka-Weber A; George JT; Ofstad AP; Wanner C; Zannad F
    J Am Heart Assoc; 2021 Apr; 10(7):e020053. PubMed ID: 33754809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
    Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
    Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
    Verma S; Mazer CD; Fitchett D; Inzucchi SE; Pfarr E; George JT; Zinman B
    Diabetologia; 2018 Aug; 61(8):1712-1723. PubMed ID: 29777264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
    McGuire DK; Zinman B; Inzucchi SE; Wanner C; Fitchett D; Anker SD; Pocock S; Kaspers S; George JT; von Eynatten M; Johansen OE; Jamal W; Mattheus M; Elsasser U; Hantel S; Lund SS
    Lancet Diabetes Endocrinol; 2020 Dec; 8(12):949-959. PubMed ID: 33217335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.
    Nangaku M; Herrington WG; Goto S; Maruyama S; Kashihara N; Ueki K; Wada J; Watada H; Nakashima E; Lee R; Massey D; Mayne KJ; Tomita A; Haynes R; Hauske SJ; Kadowaki T
    Clin Exp Nephrol; 2024 Jun; 28(6):588-595. PubMed ID: 38643286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
    Butler J; Zannad F; Fitchett D; Zinman B; Koitka-Weber A; von Eynatten M; Zwiener I; George J; Brueckmann M; Cheung AK; Wanner C
    Circ Heart Fail; 2019 Jun; 12(6):e005875. PubMed ID: 31163986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial.
    Ferreira JP; Verma S; Fitchett D; Ofstad AP; Lauer S; Zwiener I; George J; Wanner C; Zinman B; Inzucchi SE
    Cardiovasc Diabetol; 2020 Nov; 19(1):200. PubMed ID: 33243221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey.
    Wong ND; Fan W; Pak J
    Diab Vasc Dis Res; 2020; 17(4):1479164120945674. PubMed ID: 32722930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin in Patients with Chronic Kidney Disease.
    Heerspink HJL; Stefánsson BV; Correa-Rotter R; Chertow GM; Greene T; Hou FF; Mann JFE; McMurray JJV; Lindberg M; Rossing P; Sjöström CD; Toto RD; Langkilde AM; Wheeler DC;
    N Engl J Med; 2020 Oct; 383(15):1436-1446. PubMed ID: 32970396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    Wanner C; Inzucchi SE; Lachin JM; Fitchett D; von Eynatten M; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; Zinman B;
    N Engl J Med; 2016 Jul; 375(4):323-34. PubMed ID: 27299675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
    Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.